The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: A multicentre pragmatic randomised controlled trial and economic analysis

Health Technology Assessment

Volumn 11, Issue 24, 2007, Pages

  McLoughlin, D M ^a   Mogg, A ^a   Eranti, S ^a   Pluck, G ^a   Purvis, R ^a   Edwards, D ^b   Landau, S ^c   Brown, R ^c   Rabe Heskith, S ^c   Howard, R ^a   Philpot, M ^d   Rothwell, J ^e   Romeo, R ^a   Knapp, M ^a  

^a Institute of Pyschiatry   (United Kingdom)

^b Pembury Hospital   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; LITHIUM SALT; METHOHEXITAL; MIRTAZAPINE; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SUXAMETHONIUM; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN; VENLAFAXINE; ZOPICLONE;

ADULT; AGED; ARTICLE; ATTENTION; BECK DEPRESSION INVENTORY; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE SEVERITY; EFFECT SIZE; ELECTROCONVULSIVE THERAPY; FEMALE; FOLLOW UP; HAMILTON SCALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INTERMETHOD COMPARISON; MAJOR DEPRESSION; MALE; MANIA; MULTICENTER STUDY; NATIONAL HEALTH SERVICE; OUTCOME ASSESSMENT; PATIENT SAFETY; PREFRONTAL CORTEX; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SHORT FORM 36; SINGLE BLIND PROCEDURE; THERAPY EFFECT; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT DURATION; VISUAL ANALOG SCALE; COST BENEFIT ANALYSIS; ECONOMICS; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED KINGDOM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; DEPRESSION; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; LONDON; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; STATE MEDICINE; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME;

EID: 34547536597     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta11240     Document Type: Article

References (112)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
2. World Health Organization. The World Health Report 2000 - Health System: Improving Performance. Geneva: World Health Organization; 2000.
3. Kind P, Sorensen J. The costs of depression. Int Clin Psychopharmacol 1993;7:191-5.
4. Keller MB. Depression - a long-term illness. Br J Psychiatry 1994;165:9-15.
5. Kupfer DJ, Frank E, Perel JM. The advantage of early treatment intervention in recurrent depression. Arch Gen Psychiatry 1989; 46:771-5.
6. Baldwin RC, Simpson S. Treatment resistant depression in the elderly: a review of its conceptualisation, management and relationship to organic brain disease.J Affect Disord 1997; 46:163-73.
7. Souery D, Amsterdam J, de Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neurosychopharmacol 1999;9:83-91.
8. Prudic J, Sackeim HA, Devanand DP. Medication resistance and clinical-response to electroconvulsive-therapy. Psychiatry Res 1990;31:287-96.
9. UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003; 361:799-808.
10. National Institute for Health and Clinical Excellence. Guidance on the use of electroconvulsive therapy. London: NICE; 2003.
11. Calev A, Kochavlev E, Tubi N, et al. Change in attitude toward electroconvulsive-therapy - effects of treatment, time since treatment, and severity of depression. Convulsive Ther 1991;7:184-9.
12. Pettinati HM, Tamburello TA, Ruetsch CR, Kaplan FN. Patient attitudes toward electroconvulsive-therapy. Psychopharmacol Bull 1994; 30:471-5.
13. Walter G, Koster K, Rey J M. Electroconvulsive therapy in adolescents: experience, knowledge, and attitudes of recipients. J Am Acad Child Adolesc Psychiatry 1999;38:594-9.
14. Walter G, Koster K, Rey JM. Views about treatment among parents of adolescents who received electroconvulsive therapy. Psychiatric Serv 1999; 50:701-2.
15. Veiel HOF. A preliminary profile of neuropsychological deficits associated with major depression. J Clin Exp Neuropsychol 1997; 19:587-603.
16. Elliott R. The neuropsychological profile in unipolar depression. Trends Cogn Sci 1998;2:447-54.
17. Bench CJ, Friston KJ, Brown RG, Scott LC, Frackowiak RSJ, Dolan RJ. The anatomy of melancholia - focal abnormalities of cerebral blood-flow in major depression. Psychol Med 1992; 22:607-15.
18. Goodwin GM. Neuropsychological and neuroimaging evidence for the involvement of the frontal lobes in depression. J Psychopharmacol 1997; 11:115-22.
19. Devanand DP, Fitzsimons L, Prudic J, Sackeim HA. Subjective side effects during electroconvulsive therapy. Convulsive Ther 1995; 11: 232-40.
20. Rubin EH, Kinscherf DA, Figiel GS, Zorumski CF. The nature and time course of cognitive side effects during electroconvulsive therapy in the elderly. J Geriatr Psychiatry Neurol 1993;6:78-83.
21. Stoudemire A, Hill CD, Morris R, Martinosaltzman D, Markwalter H, Lewison B. Cognitive outcome following tricyclic and electroconvulsive treatment of major depression in the elderly. Am J Psychiatry 1991;148:1336-40.
22. Stoudemire A, Hill CD, Morris R, Dalton ST. Improvement in depression-related cognitive dysfunction following ECT. J Neuropsychiatry Clin Neurosci 1995;7:31-4.
23. Rose D, Wykes T, Leese M, Bindman J, Fleischmann P. Patients' perspectives on electroconvulsive therapy: systematic review. BMJ 2003;326:1363-5.
24. Lisanby SH, Maddox JH, Prudic J, Devanand DP, Sackeim HA. The effects of electroconvulsive therapy on memory of autobiographical and public events. Arch Gen Psychiatry 2000;57:581-90.
25. Sackeim HA, Prudic J, Devanand DP, et al. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry 2000;57:425-34.
26. George MS, Lisanby SH, Sackeim HA. Transcranial magnetic stimulation - applications in neuropsychiatry. Arch Gen Psychiatry 1999; 56:300-11.
27. Reid PD, Shajahan PM, Glabus MF, Ebmeier KP. Transcranial magnetic stimulation in depression. Br J Psychiatry 1998;173:449-52.
28. Rothwell JC. Techniques and mechanisms of action of transcranial stimulation of the human motor cortex. J Neurosci Methods 1997; 74:113-22.
29. Barker AT, Jalinous R. Non-invasive magnetic stimulation of human motor cortex. Lancet 1985; i:1106-7.
30. Mills KR. Magnetic brain stimulation: a tool to explore the action of the motor cortex on single human spinal motoneurones. Trends Neurosci 1991; 14:401-5.
31. Chen R, Classen J, Gerloff C, et al. Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation. Neurology 1997; 48:1398-403.
32. Hallett M. Transcranial magnetic stimulation and the human brain. Nature 2000;406:147-50.
33. Walsh V, Cowey A. Transcranial magnetic stimulation and cognitive neuroscience. Nat Rev Neurosci 2000;1:73-9.
34. Nahas Z, Speer A, Lorberbaum J, et al. Safety of rTMS: MRI scans before and after 2 weeks of daily left prefrontal rTMS for depression. Biol Psychiatry 1998;43:316.
35. Gates JR, Dhuna A, Pascual-Leone A. Lack of pathological changes in human temporal lobes after transcranial magnetic stimulation. Epilepsia 1992;33:504-8.
36. Wassermann EM, Grafman J, Berry C, et al. Use and safety of a new repetitive transcranial magnetic stimulator. Electroencephalogr Clin Neurophysiol 1996;101:412-17.
37. Jahanshahi M, Ridding MC, Limousin P, et al. Rapid rate transcranial magnetic stimulation - a safety study. Electroencephalogr Clin Neurophysiol 1997;105:422-9.
38. Speer AM, Repella JD, Figueras S, et al. Lack of adverse cognitive effects of 1 Hz and 20 Hz repetitive transcranial magnetic stimulation at 100% of motor threshold over left prefrontal cortex in depression. J ECT 2001;17:259-63.
39. Wassermann EM. Side effects of repetitive transcranial magnetic stimulation. Depress Anxiety 2000;12:124-9.
40. Wassermann EM. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996. Electroencephalogr Clin Neurophysiol 1998; 108:1-16.
41. Keel JC, Smith MJ, Wassermann EM. A safety screening questionnaire for transcranial magnetic stimulation. Clin Neurophysiol 2001; 112:720.
42. Belmaker B, Fitzgerald P, George MS, et al. Managing the risks of repetitive transcranial stimulation. CNS Spectrums 2003; 8:489.
43. Hoflich G, Kasper S, Hufnagel A, Ruhrmann S, Moller HJ. Application of transcranial magnetic stimulation in treatment of drug-resistant major depression - a report of two cases. Hum Psychopharmacol 1993; 8:361-5.
44. Kolbinger HM, Hoflich G, Hufnagel A, Moller HJ, Kasper S. Transcranial magnetic stimulation (TMS) in the treatment of major depression: a pilot study. Hum Psychopharmacol 1995;10:305-10.
45. Grisaru N, Yaroslavski U, Abarbanel J, Lamberg T, Belmaker RH. Transcranial magnetic stimulation in depression and schizophrenia. Eur Neuropsychopharmacol 1994;4:287-8.
46. George MS, Wassermanti EM, Williams WA, et al. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport 1995;6:1853-6.
47. Pascual-Leone A, Rubio B, Pallardo F, Catala MD. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet 1996;348:233-7.
48. George MS, Wassermann EM, Kimbrell TA, et al. Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebo-controlled crossover trial. Am J Psychiatry 1997;154:1752-6.
49. Figiel GS, Epstein C, McDonald WM, et al. The use of rapid-rate transcranial magnetic stimulation (rTMS) in refractory depressed patients. J Neuropsychiatry Clin Neurosci 1998;10:20-5.
50. Loo C, Mitchell P, Sachdev P, McDarmont B, Parker G, Gandevia S. Double-blind controlled investigation of transcranial magnetic stimulation for the treatment of resistant major depression. Am J Psychiatry 1999;156:946-8.
51. Klein E, Kreinin I, Christyakov A, et al. Therapeutic efficacy of tight prefrontal slow repetitive transcranial magnetic stimulation in major depression - a double-blind controlled study. Arch Gen Psychiatry 1999;56:315-20.
52. McNamara B, Ray JL, Arthurs OJ, Boniface S. Transcranial magnetic stimulation for depression and other psychiatric disorders. Psychol Med 2001; 31:1141-6.
53. Holtzheimer PE, Russo J, Avery DH. A meta-analysis of repetitive transcranial magnetic stimulation in the treatment of depression. Psychopharmacol Bull 2001;35:149-69.
54. Burt T, Lisanby SH, Sackeim HA. Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis. Int J Neuropsychopharmacol 2002; 5:73-103.
55. Kozel FA, George MS. Meta-analysis of left prefrontal repetitive transcranial magnetic stimulation (rTMS) to treat depression. J Pychiatr Pract 2002;8:270-5.
56. Martin JLR, Barbanoj MJ, Schlaepfer TE, Thompson E, Perez V, Kulisevsky J. Repetitive transcranial magnetic stimulation for the treatment of depression - systematic review and meta-analysis. Br J Pychiatry 2003;182:480-91.
57. Couturier JL. Efficacy of rapid-rate repetitive transcranial magnetic stimulation in the treatment of depression: a systematic review and meta-analysis. J Psychiatry Neurosci 2005;30:83-90.
58. Aarre TF, Dahl AA, Johansen JB, Kjonniksen I, Neckelmann D. Efficacy of repetitive transcranial magnetic stimulation in depression: a review of the evidence. Nord J Psychiatry 2005;57:227-32.
59. Loo CK, Taylor JL, Gandevia SC, McDarmont BN, Mitchell PB, Sachdev PS. Transcranial magnetic stimulation (TMS) in controlled treatment studies: are some "sham" forms active? Biol Psychiatry 2000; 47:325-31.
60. Lisanby SH, Gutman D, Luber B, Schroeder C, Sackeim HA. Sham TMS: intracerebral measurement of the induced electrical field and the induction of motor-evoked potentials. Biol Psychiatry 2001; 49:460-3.
61. Grunhaus L, Dannon PN, Schreiber S, et al. Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder. Biol Psychiatry 2000;47:314-24.
62. Pridmore S, Bruno R, Turnier-Shea Y, Reid P, Rybak M. Comparison of unlimited numbers of rapid transcranial magnetic stimulation (rTMS) and ECT treatment sessions in major depressive episode. Int J Neuropsychopharmacol 2000;3:129-34.
63. Janicak PG, Dowd SM, Martis B, et al. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: preliminary results of a randomized trial. Biol Psychiatry 2002;51:659-67.
64. Grunhaus L, Schreiber S, Dolberg OT, Polak D, Dannon PN. A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression. Biol Psychiatry 2003;53:324-31.
65. Dannon PN, Dolberg OT, Schreiber S, Grunhaus L. Three and six-month outcome following courses of either ECT or rTMS in a population of severely depressed individuals - preliminary report. Biol Pychiatry 2002;51:687-90.
66. McCall WV, Reboussin BA, Cohen W, Lawton P Electroconvulsive therapy is associated with superior symptomatic and functional change in depressed patients after psychiatric hospitalization. J Affect Disord 2001;63:17-25.
67. McCall WV, Dunn A, Rosenquist PB. Quality of life and function after electroconvulsive therapy. Br J Psychiatry 2004;185:405-9.
68. Greenhalgh J, Knight C, Hind D, Beverley C, Walters S. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. Health Technol Assess 2005;9(9).
69. Kozel FA, George MS, Simpson KN. Decision analysis of the cost-effectiveness of repetitive transcranial magnetic stimulation versus electroconvulsive therapy for treatment of nonpsychotic severe depression. CNS Spectrums 2004;9:476-82.
70. Roland M, Torgerson DJ. What are pragmatic trials? BMJ 1998; 316:285.
71. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV-TR Axis I disorders, research version, non-patient edition. (SCID-I/NP). New York: Biometrics Research, New York State Psychiatric Institute; 2001.
72. Pridmore S, Fernandes JA, Nahas Z, Liberatos C, George MS. Motor threshold in transcranial magnetic stimulation: a comparison of a neurophysiological method and a visualization of movement method. J ECT 1998;14:25-7.
73. Royal College of Psychiatrists. The ECT Handbook: The Second Report of the Royal College of Psychiatrists' Special Committee on ECT Council Report CR39. London: Royal College of Psychiatrists; 1995.
74. Sackeim HA, Prudic J, Devanand DP, et al. Effects of stimulus-intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive-therapy. N Engl J Med 1993; 328:839-46.
75. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
76. Beck AT, Steer RA, Brown GK. Beck depression inventory manual. 2nd ed. San Antonio, TX: The Psychological Corporation; 1996.
77. Arruda JE, Stern RA, Legendre SA. Assessment of mood state in patients undergoing electroconvulsive therapy: the utility of Visual Analog Mood Scales developed for cognitively impaired patients. Convulsive Ther 1996; 12:207-12.
78. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799-812.
79. Sackeim HA, Ross FR, Hopkins N, Calev L, Devanand DP. Subjective side effects acutely following ECT: associations with treatment modality and clinical response. Convulsive Ther 1987;3:100-10.
80. Roth M, Huppert FA, Tyrn E, MountJoy CQ. CAMDEX: The Cambridge Examination for Mental Disorders of the Elderly. Cambridge: Cambridge University Press; 1988.
81. Folstein MF, Folstein SE, McHugh PR. "Mini mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 1975;12:189-98.
82. Brown RG, Scott LC, Bench CJ, Dolan RJ. Cognitive function in depression: its relationship to the presence and severity of intellectual decline. Psychol Med 1994;24:829-47.
83. Wechsler D. The Wechsler Adult Intelligence Test - Revised. New York: The Psychological Corporation; 1981.
84. Kopelman M, Wilson B, Baddeley A. AMI: The Autobiographical Memory Interview. Bury St Edmunds: Thames Valley Test Company; 1990.
85. Reitan RM. Validity of the Trail Making Test as an indication of organic brain damage. Percept Mol Skills 1958;8:271-6.
86. Smith A. The Symbol Digit Modalities Test: a neuropsychological test for economic screening of learning and other cerebral disorders. Learn Disord 1968;3:83-91.
87. Matthews CG, Kløve H. Instruction manual for the Adult Neuropsychology Test Battery. Madison, WI: University of Wisconsin Medical School; 1964.
88. Prudic J, Haskett RF, Mulsant B, et al. Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry 1996; 153:985-92.
89. Eranti SV, McLoughlin DM. Electroconvulsive therapy - state of the art. Br J Psychiatry 2003; 182:8-9.
90. Eranti SV, McLoughlin DM. Changing use of ECT. Br J Psychiatry 2003;183:73.
91. Beecham JK, Knapp MRJ. Costing psychiatric interventions. In Thornicroft G, Brewin C, Wing J, editors. Measuring mental health needs. London: Gaskill; 1992. pp. 170-90.
92. Beecham J, Knapp M. Costing psychiatric interventions. In Thornicroft G, editor. Measuring mental health needs. 2nd ed. London: Gaskell; 2001. pp. 200-24.
93. Curtis L, Netten A. Unit costs of health and social care 2004. Canterbury: PSSRU, University of Kent; 2004.
94. Ware JE, Gandek B, Aaronson NK, et al. The SF-36 Health Survey: development and use in mental health research and the IQOLA Project. Int J Ment Health 1994;23:49-73.
95. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21:271-92.
96. Van Hout BA, Al MJ, Gordon GS, Ruten FFH. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994;3:309-19.
97. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves - facts, fallacies and frequently asked questions. Health Econ 2004; 13:405-15.
98. Briggs A. Economic evaluation and clinical trials: size matters - the need for greater power in cost analyses poses an ethical dilemma. BMJ 2000; 321:1362-3.
99. Sturm R, Unutzer J, Katon W. Effectiveness research and implications for study design: sample size and statistical power. Gen Hosp Psychiatry 1999; 21:274-83.
100. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet 2002;360:711-15.
101. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000; 19:3219-36.
102. Dunn G, Mirandola M, Amaddeo F, Tansella M. Describing, explaining or predicting mental health care costs: a guide to regression models. Br J Psychiatry 2003;183:398-404.
103. Gershon AA, Dannon PN, Grunhaus L. Transcranial magnetic stimulation in the treatment of depression. Am J Pychiatry 2003; 160:835-45.
104. Brodaty H, Berle D, Hickie I, Mason C. 'Side effects' of ECT are mainly depressive phenomena and are independent of age. J Affect Disord 2001; 66:237-45.
105. Schulze-Rauschenbach SC, Harms U, Schlaepfer TE, Maier W, Falkai P, Wagner M. Distinctive neurocognitive effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in major depression. Br J Psychiatry 2005;186:410-16.
106. Steif BL, Sackeim HA, Portnoy S, Decina P, Malitz S. Effects of depression and ECT on anterograde memory. Biol Psychiatry 1986; 21:921-30.
107. Hausmann A, Pascual-Leone A, Kemmler G, et al. No deterioration of cognitive performance in an aggressive unilateral and bilateral antidepressant rTMS add-on trial. J Clin Psychiatry 2004; 65:772-82.
108. Martis B, Alam D, Dowd SM, et al. Neurocognitive effects of repetitive transcranial magnetic stimulation in severe major depression. Clin Neurophysiol 2003;114:1125-32.
109. Thomas CM, Morris S. Cost of depression among adults in England in 2000. Br J Psychiatry 2003; 183:514-19.
110. Romeo R, Patel A, Knapp M, Thomas C. The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care. Int Clin Psychopharmacol 2004;19:125-34.
111. Barrett B, Byford S, Knapp M. Evidence of cost-effective treatments for depression: a systematic review. J Affect Disord 2005; 84:1-13.
112. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004;13:437-52.